Cardiol Therapeutics
CRDL
38 hedge funds and large institutions have $8.8M invested in Cardiol Therapeutics in 2025 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 7 closing their positions.
18% more capital invested
Capital invested by funds: $7.44M → $8.8M (+$1.36M)
0% more funds holding
Funds holding: 38 → 38 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
1.64% less ownership
Funds ownership: 9.46% → 7.82% (-1.6%)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
Tejara Capital
London,
United Kingdom
|
+$82.5K |
| 2 |
Morgan Stanley
New York
|
+$46.9K |
| 3 |
Mercer Global Advisors
Denver,
Colorado
|
+$26.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.3K |
| 5 |
Goldman Sachs
New York
|
+$21.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$570K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$417K |
| 3 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$179K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$172K |
| 5 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$146K |
CRDL Hedge Fund Activity: Q2 2025 in Review
38 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q2 2025, worth a combined $8.8M — up 18% from $7.44M a quarter earlier.
Fund positioning in CRDL was balanced in Q2 2025: 7 funds opened new positions, 7 closed out, 9 added to existing stakes and 11 trimmed.
The largest buyer was Tejara Capital, adding an estimated $82.5K. The largest seller was MMCAP International, cutting an estimated $570K.
- 38 institutional investors held Cardiol Therapeutics (CRDL) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $8.8M of Cardiol Therapeutics stock for Q2 2025, up 18% quarter-over-quarter.
- 7 funds opened new Cardiol Therapeutics positions in Q2 2025 and 7 closed out, a net change of 0 holders.
- The largest Cardiol Therapeutics buyer in Q2 2025 was Tejara Capital, an estimated $82.5K added.
- The largest Cardiol Therapeutics seller in Q2 2025 was MMCAP International, an estimated $570K sold.
Based on aggregated 13F filings for Q2 2025.